Millennium Management’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Millennium Management’s Portfolio CALT Stock Details CALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-15,570	Closed	-$430K	–	7252
2021 Q1	$430K	Sell	15,570 -4,914	-24%	-$147K	﹤0.01%	4942
2020 Q4	$696K	Sell	20,484 -17,737	-46%	-$540K	﹤0.01%	3963
2020 Q3	$917	Sell	38,221 -13,044	-25%	-$304K	﹤0.01%	3203
2020 Q2	$1.19M	Buy	+51,265	New	+$1.02M	﹤0.01%	2889

Other funds holding CALT

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

IIM

Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

NFG

Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management's CALT Position: Q2 2021 in Review

Millennium Management sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q2 2021, closing a stake of 15,570 shares — an estimated $430K sold.

Millennium Management first reported a position in CALT in Q2 2020 and held it in 4 quarters. The position peaked at $1.19M in Q2 2020. 14 funds tracked by Wall St. Rank hold CALT as of Q2 2021.

Millennium Management reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q2 2021 after selling out during the quarter.
Millennium Management sold 15,570 Calliditas Therapeutics AB American Depositary Shares shares in Q2 2021, an estimated $430K.
Millennium Management first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q2 2020 and held it in 4 quarters.
Millennium Management's Calliditas Therapeutics AB American Depositary Shares position peaked at $1.19M in Q2 2020.
14 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q2 2021.

Based on Millennium Management's 13F filing for Q2 2021, filed 16 Aug 2021.